Anti-viral strategies.

[1]  R. Morgan,et al.  Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. , 1994, Human gene therapy.

[2]  T. Cech,et al.  Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. , 1993, Science.

[3]  H. Lane,et al.  A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. , 1993, Human gene therapy.

[4]  J. Lisziewicz,et al.  Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Sinclair,et al.  Inhibition of human cytomegalovirus major immediate early gene expression by antisense RNA expression vectors. , 1993, The Journal of general virology.

[6]  S. Chen,et al.  Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  O. Yamada,et al.  A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Y. Cheng,et al.  Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification , 1993, Antimicrobial Agents and Chemotherapy.

[9]  L. Cowsert,et al.  Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. , 1993, Cancer research.

[10]  W. Greene,et al.  Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo , 1993, Journal of virology.

[11]  J. Kreider,et al.  Cleavage of cottontail rabbit papillomavirus E7 RNA with an anti-E7 ribozyme. , 1993, Biochemical and biophysical research communications.

[12]  Z. Matsuda,et al.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Rose,et al.  Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Anthony S. Fauci,et al.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.

[15]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[16]  H. Blum,et al.  In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. , 1993, The EMBO journal.

[17]  P. Johnson,et al.  Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. , 1992, Science.

[18]  P. C. Weber,et al.  Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0. , 1992, The Journal of general virology.

[19]  J. Pagano,et al.  Epstein‐Barr Viral Latency and Cell Immortalization as Targets for Antisense Oligomers a , 1992, Annals of the New York Academy of Sciences.

[20]  M. Malim,et al.  Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication , 1992, The Journal of experimental medicine.

[21]  T. Curiel,et al.  Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. , 1992, Human gene therapy.

[22]  A. Banerjea,et al.  Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates. , 1992, Nucleic acids research.

[23]  S. Chada,et al.  CTL cross reactivity between HIV strains. , 1992, AIDS research and human retroviruses.

[24]  M. von Knebel Doeberitz,et al.  Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV e6‐e7 anti‐sense RNA , 1992, International journal of cancer.

[25]  C. Wu,et al.  Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. , 1992, The Journal of biological chemistry.

[26]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[27]  M. Feinberg,et al.  Intracellular immunization: trans-dominant mutants of HIV gene products as tools for the study and interruption of viral replication. , 1992, AIDS research and human retroviruses.

[28]  S. Riddell,et al.  Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer Research Center and the University of Washington , 1992 .

[29]  A. Panganiban,et al.  Human immunodeficiency virus vectors for inducible expression of foreign genes , 1992, Journal of virology.

[30]  S. Read,et al.  Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme , 1991, Journal of virology.

[31]  S. Chada,et al.  Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. , 1991, AIDS research and human retroviruses.

[32]  G. Sczakiel,et al.  Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. , 1991, Nucleic acids research.

[33]  Eli Gilboa,et al.  Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication , 1990, Cell.

[34]  N. DeLuca,et al.  trans-dominant inhibition of herpes simplex virus transcriptional regulatory protein ICP4 by heterodimer formation , 1990, Journal of virology.

[35]  J. Rossi,et al.  Ribozymes as potential anti-HIV-1 therapeutic agents. , 1990, Science.

[36]  W. Anderson,et al.  Retroviral vectors expressing soluble CD4: a potential gene therapy for AIDS. , 1990, AIDS research and human retroviruses.

[37]  M. Malim,et al.  Functional dissection of the HIV-1 Rev trans-activator—Derivation of a trans-dominant repressor of Rev function , 1989, Cell.

[38]  D. Bednarik,et al.  Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Gilboa,et al.  Inhibition of human T-cell leukemia virus type I replication in primary human T cells that express antisense RNA , 1989, Journal of virology.

[40]  N. Thuong,et al.  Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent. , 1987, Nucleic acids research.

[41]  R. Krance,et al.  Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. , 1994, Human gene therapy.

[42]  T. Lee,et al.  Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. , 1992, The New biologist.

[43]  D. Klatzmann,et al.  Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. V. Vinogradov,et al.  A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus‐specific proteins in MDCK cells , 1990, FEBS letters.